<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="Metastatic Colon Cancer  æ—å”éœ†, Fellow 1 2023-08-28  Basic Workup Suspected or proven metastatic adenocarcinoma  Colonoscopy Chest/abdominal/pelvic CT CBC, chemistry profile, CEA Determination of tumor gene status  for RAS and BRAF mutations and HER2 amplifications individually or as part of tissue- or blood-based next-generation sequencing   Determination of tumor MMR or MSI statuse (if not previously done) Biopsy, if clinically indicated   Consider PET-CT scan (skull base to mid-thigh)  if potentially surgically curable M1 disease in selected cases  Consider MRI of liver for liver metastases that are potentially resectable  If potentially resectable, then multidisciplinary team evaluation, including a surgeon experienced in the resection of hepatobiliary or lung metastases   Prototypical Treatment Trajectories   Definitions  FOLFOX  Infusional 5-FU/LV + OX; FOLFIRI: Infusional 5-FU/LV + irinotecan;   FOLFOXIRI:  Infusional 5-FU/LV + OX + irinotecan;   CAPEOX: Cape + OX  1st line  FOLFOX (JCO 2004;22:23) Â± Bevacizumab (JCO 2008;26:2013); CAPEOX; FOLFIRI (JCO 2004;22:229) Â± Bev (JCO 2007;25:4779); FOLFOXIRI Â± Bev (TRIBE, NEJM 2014;371:1609)   JCO 2004;22:23  :::columns"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Lecture of Metastatic Colon Cancer"><title>Lecture of Metastatic Colon Cancer</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.ba063fb2c262e32806125420a04897fb.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.b3b05d7aa4a3b117fe66eb314e8eecf6.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Lecture of Metastatic Colon Cancer</h1><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Aug 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/Lecture%20of%20Metastatic%20Colon%20Cancer.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>ğŸ“’ç›®éŒ„</summary><nav id=TableOfContents><ol><li><a href=#æ—å”éœ†-fellow-1>æ—å”éœ†, Fellow 1</a><ol><li></li></ol></li><li><a href=#basic-workup>Basic Workup</a><ol><li><a href=#suspected-or-proven-metastatic-adenocarcinoma>Suspected or proven metastatic adenocarcinoma</a></li></ol></li><li><a href=#consider-pet-ct-scan-skull-base-to-mid-thigh>Consider PET-CT scan (skull base to mid-thigh)</a></li><li><a href=#consider-mri-of-liver-for-liver-metastases-that-are-potentially-resectable>Consider MRI of liver for liver metastases that are potentially resectable</a></li><li><a href=#prototypical-treatment-trajectories>Prototypical Treatment Trajectories</a></li><li><a href=#definitions>Definitions</a><ol><li><a href=#1st-line>1st line</a></li></ol></li><li><a href=#jco-20042223>JCO 2004;22:23</a></li><li><a href=#jco-2008262013>JCO 2008;26:2013</a><ol><li></li></ol></li><li><a href=#tribe-nejm-20143711609>TRIBE, NEJM 2014;371:1609</a></li><li><a href=#if-pts-not-appropriate-for-intense-rx>If pts not appropriate for intense Rx</a></li><li><a href=#for-pts-w-l-sided-crc--wt-rasbraf>For pts w/ <strong>L-sided</strong> CRC & wt RAS/BRAF</a><ol><li></li></ol></li><li><a href=#crystal-nejm-20093601408>CRYSTAL, NEJM 2009;360:1408</a><ol><li></li></ol></li><li><a href=#prime-jco-2010284697>PRIME, JCO 2010;28:4697</a></li><li><a href=#2nd-line>2nd line</a></li><li><a href=#3rd-line>3rd line</a></li><li><a href=#msi-hdmmr>MSI-H/dMMR</a><ol><li></li></ol></li><li><a href=#1st-line-for-msi-hdmmr>1st line for MSI-H/dMMR</a><ol><li></li></ol></li><li><a href=#checkmate-142-lancet-oncol-2017181182-jco-2022402161-170>CHECKMATE 142, Lancet Oncol 2017;18:1182, JCO. 2022;40(2):161-170</a><ol><li></li></ol></li><li><a href=#braf-pathway>BRAF pathway</a></li><li><a href=#later-line-for-braf-v600e-mutation-beacon-nejm-20193811632>Later line for BRAF V600E mutation: BEACON, NEJM 2019;381:1632</a></li><li><a href=#later-line-for-her2-amplified--rasbraf-wildtype>Later line for HER2 amplified & RAS/BRAF wildtype</a></li><li><a href=#principles-of-managing-patients-with-metastatic-colorectal-cancer>Principles of Managing Patients With Metastatic Colorectal Cancer</a></li><li><a href=#initial-evaluation-and-choice-of-treatment-intent-and-modality>Initial evaluation and choice of treatment intent and modality</a></li><li><a href=#metastatic-disease-that-is-unresectable-and-previously-resected-or-adequately-controlled-primary-tumor-unresectable-metastases>Metastatic disease that is unresectable and previously resected or adequately controlled primary tumor (unresectable metastases)</a></li><li><a href=#rectal-primary-tumor>Rectal primary tumor</a></li><li><a href=#right-sided-primary-tumor>Right-sided primary tumor</a></li><li><a href=#prior-adjuvant-chemotherapy>Prior adjuvant chemotherapy</a></li><li><a href=#anticipated-need-for-surgery>Anticipated need for surgery</a></li><li><a href=#significant-peripheral-neuropathy-from-comorbid-illness-such-as-diabetes-or-adjuvant-oxaliplatin>Significant peripheral neuropathy from comorbid illness such as diabetes or adjuvant oxaliplatin</a></li><li><a href=#hyperbilirubinemia>Hyperbilirubinemia</a></li><li><a href=#fluorouracil-associated-coronary-vasospasm>Fluorouracil-associated coronary vasospasm</a></li><li><a href=#severe-pancytopenia-mucositis-after-fluorouracil-treatment>Severe pancytopenia; mucositis after fluorouracil treatment</a></li><li><a href=#for-folfox-ox-should-be-discontinued-after-first-3-months-of-rx-till-progression>For FOLFOX, OX should be discontinued after first 3 months of Rx till progression</a></li><li><a href=#severe-diarrhea-following-irinotecan-containing-regimens>Severe diarrhea following irinotecan containing regimens</a></li><li><a href=#frailty-after-second-line-treatment-third-line-if-krasnras-wild-type>Frailty after second-line treatment (third line if KRAS/NRAS wild type)</a><ol><li><a href=#somatic-variant-in-the-kras-or-nras-genes>Somatic variant in the KRAS or NRAS genes</a></li><li><a href=#somatic-variant-in-the-braf-gene>Somatic variant in the BRAF gene</a></li><li><a href=#somatic-variant-in-the-erbb2-gene>Somatic variant in the ERBB2 gene</a></li><li><a href=#microsatellite-instability-high>Microsatellite instability-high</a></li></ol></li><li><a href=#do-not-use-concurrent-anti-egfr--anti-vegf-rx>Do not use concurrent anti-EGFR + anti-VEGF Rx</a></li><li><a href=#crc-survival>CRC Survival</a></li><li><a href=#take-home-message>Take Home message</a></li><li><a href=#prototypical-treatment-trajectories-1>Prototypical Treatment Trajectories</a></li><li><a href=#the-end>THE END</a></li></ol></nav></details></aside><a href=#metastatic-colon-cancer><h1 id=metastatic-colon-cancer><span class=hanchor arialabel=Anchor># </span>Metastatic Colon Cancer</h1></a><hr><a href=#æ—å”éœ†-fellow-1><h2 id=æ—å”éœ†-fellow-1><span class=hanchor arialabel=Anchor># </span>æ—å”éœ†, Fellow 1</h2></a><a href=#2023-08-28><h5 id=2023-08-28><span class=hanchor arialabel=Anchor># </span>2023-08-28</h5></a><hr><a href=#basic-workup><h2 id=basic-workup><span class=hanchor arialabel=Anchor># </span>Basic Workup</h2></a><a href=#suspected-or-proven-metastatic-adenocarcinoma><h3 id=suspected-or-proven-metastatic-adenocarcinoma><span class=hanchor arialabel=Anchor># </span>Suspected or proven metastatic adenocarcinoma</h3></a><ul><li><code>Colonoscopy</code></li><li>Chest/abdominal/pelvic CT</li><li>CBC, chemistry profile, CEA</li><li>Determination of tumor gene status<ul><li>for <code>RAS</code> and <code>BRAF</code> mutations and <code>HER2</code> amplifications</li><li>individually or as part of tissue- or blood-based next-generation sequencing</li></ul></li><li>Determination of tumor <code>MMR</code> or <code>MSI</code> statuse (if not previously done)</li><li>Biopsy, if clinically indicated</li></ul><hr><a href=#consider-pet-ct-scan-skull-base-to-mid-thigh><h2 id=consider-pet-ct-scan-skull-base-to-mid-thigh><span class=hanchor arialabel=Anchor># </span>Consider PET-CT scan (skull base to mid-thigh)</h2></a><ul><li>if potentially surgically curable M1 disease in selected cases</li></ul><a href=#consider-mri-of-liver-for-liver-metastases-that-are-potentially-resectable><h2 id=consider-mri-of-liver-for-liver-metastases-that-are-potentially-resectable><span class=hanchor arialabel=Anchor># </span>Consider MRI of liver for liver metastases that are potentially resectable</h2></a><ul><li>If potentially resectable, then multidisciplinary team evaluation, including a surgeon experienced in the resection of hepatobiliary or lung metastases</li></ul><hr><a href=#prototypical-treatment-trajectories><h2 id=prototypical-treatment-trajectories><span class=hanchor arialabel=Anchor># </span>Prototypical Treatment Trajectories</h2></a><p><img src=https://i.imgur.com/LPCRJVa.png width=auto alt="Figure: height:550px"></p><hr><a href=#definitions><h2 id=definitions><span class=hanchor arialabel=Anchor># </span>Definitions</h2></a><ul><li>FOLFOX<ul><li>Infusional 5-FU/LV + OX; FOLFIRI: Infusional 5-FU/LV + irinotecan;</li></ul></li><li>FOLFOXIRI:<ul><li>Infusional 5-FU/LV + OX + irinotecan;</li></ul></li><li>CAPEOX: Cape + OX</li></ul><a href=#1st-line><h3 id=1st-line><span class=hanchor arialabel=Anchor># </span>1st line</h3></a><ul><li>FOLFOX (JCO 2004;22:23) Â± Bevacizumab (JCO 2008;26:2013);</li><li>CAPEOX;</li><li>FOLFIRI (JCO 2004;22:229) Â± Bev (JCO 2007;25:4779);</li><li>FOLFOXIRI Â± Bev (TRIBE, NEJM 2014;371:1609)</li></ul><hr><a href=#jco-20042223><h2 id=jco-20042223><span class=hanchor arialabel=Anchor># </span>JCO 2004;22:23</h2></a><p><img src=https://i.imgur.com/8s4HYql.png width=auto alt="Figure: height:200px"></p><p>:::columns</p><p><img src=https://i.imgur.com/wNf7HMR.png width=auto alt="Figure: height:300px"></p><p>:::split</p><p><img src=https://i.imgur.com/nTx2xlP.png width=auto alt="Figure: height:300px"></p><p>:::</p><hr><a href=#jco-2008262013><h2 id=jco-2008262013><span class=hanchor arialabel=Anchor># </span>JCO 2008;26:2013</h2></a><p>:::columns</p><hr><a href=#bevacizumab-in-mcrc-first-line-treatment><h5 id=bevacizumab-in-mcrc-first-line-treatment><span class=hanchor arialabel=Anchor># </span>Bevacizumab in MCRC First-Line Treatment</h5></a><ul><li>Addition of bevacizumab to oxaliplatin-based chemotherapy improved PFS in first-line trial in patients with MCRC</li><li>Overall survival differences did not reach statistical significance</li><li>Response rate was not improved by the addition of bevacizumab</li></ul><p>:::split</p><p><img src=https://i.imgur.com/iEiMPHD.png width=auto alt="Figure: height:110px">
<img src=https://i.imgur.com/5adiXe5.png width=auto alt="Figure: height:350px"></p><p>:::</p><hr><a href=#tribe-nejm-20143711609><h2 id=tribe-nejm-20143711609><span class=hanchor arialabel=Anchor># </span>TRIBE, NEJM 2014;371:1609</h2></a><hr><blockquote><p>Loupakis F, Cremolini C, Masi G, et al. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine. 2014;371(17):1609-1618. doi:10.1056/NEJMoa1403108</p></blockquote><p>:::columns</p><ul><li>A phase 2 study</li><li>508 patients with untreated metastatic colorectal cancer were randomly assigned to receive either FOLFIRI plus bevacizumab (control group) or FOLFOXIRI plus bevacizumab (experimental group)</li><li>Median progression-free survival was 12.1 months in the experimental group compared to 9.7 months in the control group</li><li>FOLFOXIRI plus bevacizumab improved outcomes</li></ul><p>:::split</p><p><img src=https://i.imgur.com/huHhkkd.png width=auto alt="Figure: height:250px">
<img src=https://i.imgur.com/ebhCWT7.png width=auto alt="Figure: height:250px"></p><p>:::</p><hr><a href=#if-pts-not-appropriate-for-intense-rx><h2 id=if-pts-not-appropriate-for-intense-rx><span class=hanchor arialabel=Anchor># </span>If pts not appropriate for intense Rx</h2></a><ul><li>Infusional 5-FU/LV;</li><li>Capecitabine</li></ul><hr><a href=#for-pts-w-l-sided-crc--wt-rasbraf><h2 id=for-pts-w-l-sided-crc--wt-rasbraf><span class=hanchor arialabel=Anchor># </span>For pts w/ <strong>L-sided</strong> CRC & wt RAS/BRAF</h2></a><ul><li>FOLFOX or FOLFIRI Â± cetuximab/panitumumab (CRYSTAL, NEJM 2009;360:1408; PRIME, JCO 2010;28:4697)</li></ul><p>:::columns</p><p><img src=https://i.imgur.com/w91iLpe.png width=auto alt="Figure: height:350px"></p><p>:::split</p><a href=#egfr-signal-transduction-pathway><h5 id=egfr-signal-transduction-pathway><span class=hanchor arialabel=Anchor># </span>EGFR Signal Transduction Pathway</h5></a><ul><li>EGFR is a receptor tyrosine kinase that belongs to the ERBB family</li><li>Ligand binding to EGFR causes receptor dimerization</li><li>The resulting receptor autophosphorylation initiates signal transduction</li><li>Cetuximab inhibits receptor phosphorylation</li></ul><p>:::</p><hr><a href=#crystal-nejm-20093601408><h2 id=crystal-nejm-20093601408><span class=hanchor arialabel=Anchor># </span>CRYSTAL, NEJM 2009;360:1408</h2></a><p><img src=https://i.imgur.com/kipnLPs.png width=auto alt="Figure: bg right:60% 80%"></p><ul><li>Cetuximab (Cmab) added to chemotherapy (CT) as first-line treatment</li><li>mCRC and KRAS wild-type (wt) tumors improved efficacy</li></ul><hr><a href=#median-progression-free-survival-was-significantly-decreased-in-patients-with-kras-mutation-81-vs-105-months-p--004-who-received-cbc><h4 id=median-progression-free-survival-was-significantly-decreased-in-patients-with-kras-mutation-81-vs-105-months-p--004-who-received-cbc><span class=hanchor arialabel=Anchor># </span>Median progression-free survival was significantly decreased in patients with KRAS mutation (8.1 vs. 10.5 months, P = 0.04) who received CBC</h4></a><p><img src=https://i.imgur.com/kIq4UBr.png width=auto alt="Figure: bg 60%"></p><hr><a href=#prime-jco-2010284697><h2 id=prime-jco-2010284697><span class=hanchor arialabel=Anchor># </span>PRIME, JCO 2010;28:4697</h2></a><p><img src=https://i.imgur.com/GOg6e9L.png width=auto alt="Figure: bg right:70% 90% auto"></p><ul><li>Randomized, Phase III</li><li>Panitumumab With FOLFOX4 vs. FOLFOX4</li><li>Alone As First-Line Treatment in Patients With Previously Untreated Metastatic CRC</li></ul><hr><a href=#2nd-line><h2 id=2nd-line><span class=hanchor arialabel=Anchor># </span>2nd line</h2></a><ul><li>FOLFIRI or irinotecan<ul><li>for pts who received prior FOLFOX;</li></ul></li><li>FOLFOX/CAPEOX<ul><li>for pts w/ prior FOLFIRI;</li></ul></li><li>FOLFOX/CAPEOX, or FOLFIRI<ul><li>for prior 5-FU/LV or Cape;</li></ul></li><li>all regimens Â± Bev/ziv-aflibercept/ramucirumab<ul><li>note that Bev is preferred over ziv-aflibercept/ramucirumab because of tox &/or cost</li></ul></li><li>irinotecan-based regimens Â±; cetuximab/panitumumab<ul><li>if not previously used</li></ul></li></ul><hr><a href=#3rd-line><h2 id=3rd-line><span class=hanchor arialabel=Anchor># </span>3rd line</h2></a><ul><li>Irinotecan Â± panitumumab/cetuximab (BOND, NEJM 2004;351:337)</li><li>single-agent panitumumab/cetuximab, or</li><li>single-agent regorafenib or TAS-102;<ul><li>overall benefits of regorafenib or TAS-102 are modest w/ significant s/e</li></ul></li></ul><p>:::columns</p><p><img src=https://i.imgur.com/bUvqqRM.png width=auto alt="Figure: height:250px"></p><p>:::split</p><p><img src=https://i.imgur.com/n2YvuY0.png width=auto alt="Figure: height:250px"></p><p>:::</p><hr><a href=#msi-hdmmr><h2 id=msi-hdmmr><span class=hanchor arialabel=Anchor># </span>MSI-H/dMMR</h2></a><hr><a href=#when-is-immunotherapy-an-appropriate-therapy-for-metastatic-crc><h5 id=when-is-immunotherapy-an-appropriate-therapy-for-metastatic-crc><span class=hanchor arialabel=Anchor># </span>When Is Immunotherapy an Appropriate Therapy for Metastatic CRC?</h5></a><p><img src=https://i.imgur.com/VF03csE.png width=auto alt="Figure: height:200px"></p><p><img src=https://i.imgur.com/HEswiN1.png width=auto alt="bg auto right 75%"></p><hr><a href=#1st-line-for-msi-hdmmr><h2 id=1st-line-for-msi-hdmmr><span class=hanchor arialabel=Anchor># </span>1st line for MSI-H/dMMR</h2></a><ul><li>Pembrolizumab (KEYNOTE-177, NEJM 2020;383:2207) or nivolumab Â± ipilimumab (CHECKMATE 142, Lancet Oncol 2017;18:1182)</li></ul><p>:::columns</p><a href=#keynote-177-nejm-20203832207><h4 id=keynote-177-nejm-20203832207><span class=hanchor arialabel=Anchor># </span>KEYNOTE-177, NEJM 2020;383:2207</h4></a><ul><li>Pembrolizumab is superior to chemotherapy with respect to progression-free survival</li><li>Data on overall survival were still evolving, and remain blinded until final analysis</li><li>adverse events of grade 3 or higher: lower percentage in the pembrolizumab</li></ul><p>:::split</p><p><img src=https://i.imgur.com/yeT4nYJ.png width=auto alt=height:360px></p><p>:::</p><hr><a href=#checkmate-142-lancet-oncol-2017181182-jco-2022402161-170><h2 id=checkmate-142-lancet-oncol-2017181182-jco-2022402161-170><span class=hanchor arialabel=Anchor># </span>CHECKMATE 142, Lancet Oncol 2017;18:1182, JCO. 2022;40(2):161-170</h2></a><ul><li>dual I-O combination as 1L therapy for MSI-H/dMMR mCRC.</li><li>Nivolumab plus low-dose ipilimumab demonstrated a robust clinical benefit<ul><li>characterized by an ORR of 69% (CR rate, 13%), DCR of 84%</li></ul></li></ul><p>:::columns</p><a href=#progression-free-survival><h4 id=progression-free-survival><span class=hanchor arialabel=Anchor># </span>Progression-free survival</h4></a><p><img src=https://i.imgur.com/T9jGuyJ.png width=auto alt="Figure: height:300px"></p><p>:::split</p><a href=#overall-survival><h4 id=overall-survival><span class=hanchor arialabel=Anchor># </span>overall survival</h4></a><p><img src=https://i.imgur.com/6SQHLBF.png width=auto alt="Figure: height:300px"></p><p>:::</p><hr><a href=#braf-pathway><h2 id=braf-pathway><span class=hanchor arialabel=Anchor># </span>BRAF pathway</h2></a><hr><a href=#later-line-for-braf-v600e-mutation-beacon-nejm-20193811632><h2 id=later-line-for-braf-v600e-mutation-beacon-nejm-20193811632><span class=hanchor arialabel=Anchor># </span>Later line for BRAF V600E mutation: BEACON, NEJM 2019;381:1632</h2></a><p><img src=https://i.imgur.com/g4620qh.png width=auto alt="Figure: height:150px"></p><p><img src=https://i.imgur.com/otCKHH7.png width=auto alt="Figure: height:350px"></p><hr><a href=#later-line-for-her2-amplified--rasbraf-wildtype><h2 id=later-line-for-her2-amplified--rasbraf-wildtype><span class=hanchor arialabel=Anchor># </span>Later line for HER2 amplified & RAS/BRAF wildtype</h2></a><ul><li>Trastuzumab + pertuzumab;</li><li>trastuzumab + lapatinib;</li><li>trastuzumab deruxtecan (Enhertu) DESTINY-CRC01</li></ul><p>:::columns</p><p><img src=https://i.imgur.com/cVQBQSa.png width=auto alt="Figure: height:350px"></p><p>:::split</p><p><img src=https://i.imgur.com/Dq8doM3.png width=auto alt="Figure: height:350px"></p><p>:::</p><hr><style scoped>h2{font-size:3em;font-weight:700}</style><a href=#principles-of-managing-patients-with-metastatic-colorectal-cancer><h2 id=principles-of-managing-patients-with-metastatic-colorectal-cancer><span class=hanchor arialabel=Anchor># </span>Principles of Managing Patients With Metastatic Colorectal Cancer</h2></a><hr><a href=#initial-evaluation-and-choice-of-treatment-intent-and-modality><h2 id=initial-evaluation-and-choice-of-treatment-intent-and-modality><span class=hanchor arialabel=Anchor># </span>Initial evaluation and choice of treatment intent and modality</h2></a><ul><li>Poor functional status, including life expectancy <strong>&lt;6 mo</strong><ul><li>palliative care</li><li>Manage bowel obstruction or bleeding with stent or palliative radiation</li></ul></li><li>Symptomatic bowel obstruction or significant bleeding<ul><li>Surgical management with diverting ostomy</li></ul></li><li>Significant comorbidity, frailty, or both but life expectancy <strong>â‰¥6 mo</strong><ul><li>Single-agent fluorouracil or capecitabine palliates symptoms and extends life expectancy</li><li>Systemic therapy can be intensified or discontinued based on tolerance</li></ul></li></ul><hr><a href=#metastatic-disease-that-is-unresectable-and-previously-resected-or-adequately-controlled-primary-tumor-unresectable-metastases><h2 id=metastatic-disease-that-is-unresectable-and-previously-resected-or-adequately-controlled-primary-tumor-unresectable-metastases><span class=hanchor arialabel=Anchor># </span>Metastatic disease that is unresectable and previously resected or adequately controlled primary tumor (unresectable metastases)</h2></a><ul><li>systemic chemotherapy (such as FOLFOX or FOLFIRI) or immunotherapy in MSI-H/MMR-D</li><li>Obtain molecular tumor profiling to inform treatment selection</li><li>typical to survive 2 to 3 years with intensive treatment</li></ul><a href=#rectal-primary-tumor><h2 id=rectal-primary-tumor><span class=hanchor arialabel=Anchor># </span>Rectal primary tumor</h2></a><ul><li>Include radiation oncology</li><li>Radiation is rarely required as initial therapy when metastases are present<ul><li>may induce myelosuppression which impairs future tolerance of systemic treatment</li></ul></li></ul><hr><a href=#right-sided-primary-tumor><h2 id=right-sided-primary-tumor><span class=hanchor arialabel=Anchor># </span>Right-sided primary tumor</h2></a><ul><li>Avoid unnecessary resection of the primary tumor; obstruction is rare</li><li>Avoid use of first-line cetuximab and panitumumab given low response rates</li><li>Right-sided colon cancer (RC) is distinct from left-sided colorectal cancer (LC)<ul><li>in embryology, pathology, and genetics</li><li>RC has more KRAS and BRAF mutations and</li><li>RC has poorer clinical outcomes than LC</li></ul></li><li>Shorter OS in multivariate analysis<ul><li>BRAF mutations</li><li>RC</li><li>poorly differentiated histology</li><li>and peritoneal involvement were associated with</li></ul></li></ul><blockquote><p>JCO 2016;34(suppl, abstr 3504, 3505, 3506; JAMA Oncol 2017;3:211)</p></blockquote><hr><a href=#prior-adjuvant-chemotherapy><h2 id=prior-adjuvant-chemotherapy><span class=hanchor arialabel=Anchor># </span>Prior adjuvant chemotherapy</h2></a><ul><li>If metastases develop within 6 months of adjuvant single-agent fluorouracil, intensification to multiagent regimens such as FOLFOX or FOLFIRI is necessary</li><li>If metastases develop within 6 months of adjuvant FOLFOX, use FOLFIRI</li></ul><a href=#anticipated-need-for-surgery><h2 id=anticipated-need-for-surgery><span class=hanchor arialabel=Anchor># </span>Anticipated need for surgery</h2></a><ul><li>Avoid VEGF inhibitors for 6 to 8 weeks before and after major surgery</li></ul><hr><a href=#significant-peripheral-neuropathy-from-comorbid-illness-such-as-diabetes-or-adjuvant-oxaliplatin><h2 id=significant-peripheral-neuropathy-from-comorbid-illness-such-as-diabetes-or-adjuvant-oxaliplatin><span class=hanchor arialabel=Anchor># </span>Significant peripheral neuropathy from comorbid illness such as diabetes or adjuvant oxaliplatin</h2></a><ul><li>Avoid or delay use of oxaliplatin to prevent worsening peripheral neuropathy</li><li>Vigilance with close monitoring is required with dose reduction or discontinuation before neuropathy limits function</li></ul><a href=#hyperbilirubinemia><h2 id=hyperbilirubinemia><span class=hanchor arialabel=Anchor># </span>Hyperbilirubinemia</h2></a><ul><li>Avoid or delay use of irinotecan, which is metabolized in the liver</li></ul><hr><a href=#fluorouracil-associated-coronary-vasospasm><h2 id=fluorouracil-associated-coronary-vasospasm><span class=hanchor arialabel=Anchor># </span>Fluorouracil-associated coronary vasospasm</h2></a><ul><li>Comanage with cardiology. Infusional fluorouracil is more likely to lead to vasospasm and should be avoided. Consider vasodilators and inpatient management</li></ul><a href=#severe-pancytopenia-mucositis-after-fluorouracil-treatment><h2 id=severe-pancytopenia-mucositis-after-fluorouracil-treatment><span class=hanchor arialabel=Anchor># </span>Severe pancytopenia; mucositis after fluorouracil treatment</h2></a><ul><li>Evaluate for dihydropyrimidine dehydrogenase deficiency and reduce the dose based on results. Consider IROX (irinotecan and oxaliplatin) regimen in cases of homozygous dihydropyrimidine dehydrogenase deficiency</li></ul><hr><a href=#for-folfox-ox-should-be-discontinued-after-first-3-months-of-rx-till-progression><h2 id=for-folfox-ox-should-be-discontinued-after-first-3-months-of-rx-till-progression><span class=hanchor arialabel=Anchor># </span>For FOLFOX, OX should be discontinued after first 3 months of Rx till progression</h2></a><ul><li>To reduce risk of severe neurotoxicity</li><li>Can be resumed at or after progression (OPTIMOX1, JCO 2006;24:394)</li></ul><p>:::columns</p><p><img src=https://i.imgur.com/NuFZ88e.png width=auto alt="Figure: height:350px"></p><p>:::split</p><p><img src=https://i.imgur.com/2PR901B.png width=auto alt="Figure: height:350px"></p><p>:::</p><hr><a href=#severe-diarrhea-following-irinotecan-containing-regimens><h2 id=severe-diarrhea-following-irinotecan-containing-regimens><span class=hanchor arialabel=Anchor># </span>Severe diarrhea following irinotecan containing regimens</h2></a><ul><li>Reduce dose based on symptoms and intensify antidiarrheal medications</li><li>Consider testing for UGT1A1 polymorphisms and reduce dose based on results</li></ul><a href=#frailty-after-second-line-treatment-third-line-if-krasnras-wild-type><h2 id=frailty-after-second-line-treatment-third-line-if-krasnras-wild-type><span class=hanchor arialabel=Anchor># </span>Frailty after second-line treatment (third line if KRAS/NRAS wild type)</h2></a><ul><li>Consider palliative and supportive care over use of later-line systemic treatments with marginal survival advantage and substantial toxicity</li></ul><hr><a href=#somatic-variant-in-the-kras-or-nras-genes><h3 id=somatic-variant-in-the-kras-or-nras-genes><span class=hanchor arialabel=Anchor># </span>Somatic variant in the KRAS or NRAS genes</h3></a><ul><li>Avoid use of cetuximab or panitumumab as these agents are not effective for patients with these molecular features</li></ul><a href=#somatic-variant-in-the-braf-gene><h3 id=somatic-variant-in-the-braf-gene><span class=hanchor arialabel=Anchor># </span>Somatic variant in the BRAF gene</h3></a><ul><li>Recognize poor prognosis, prioritize clinical trials</li><li>Use second-line therapy with encorafenib plus cetuximab</li></ul><a href=#somatic-variant-in-the-erbb2-gene><h3 id=somatic-variant-in-the-erbb2-gene><span class=hanchor arialabel=Anchor># </span>Somatic variant in the ERBB2 gene</h3></a><ul><li>Drugs that block the ERBB2 receptor like trastuzumab may work but prioritize clinical trials over their off-label use</li></ul><a href=#microsatellite-instability-high><h3 id=microsatellite-instability-high><span class=hanchor arialabel=Anchor># </span>Microsatellite instability-high</h3></a><ul><li>Prioritize immunotherapy containing regimens</li></ul><hr><a href=#do-not-use-concurrent-anti-egfr--anti-vegf-rx><h2 id=do-not-use-concurrent-anti-egfr--anti-vegf-rx><span class=hanchor arialabel=Anchor># </span>Do not use concurrent anti-EGFR + anti-VEGF Rx</h2></a><p><img src=https://i.imgur.com/T8tPFzw.png width=auto alt="Figure: height:150px"></p><p>:::columns</p><p><img src=https://i.imgur.com/CoToHFC.png width=auto alt="Figure: height:350px"></p><p>:::split</p><p><img src=https://i.imgur.com/xvG8E2K.png width=auto alt="Figure: height:350px"></p><p>:::</p><hr><p><img src=https://i.imgur.com/43xWsGk.png width=auto alt="bg 80%"></p><hr><a href=#crc-survival><h2 id=crc-survival><span class=hanchor arialabel=Anchor># </span>CRC Survival</h2></a><ul><li>5-year survival rate for metastatic CRC is 14%</li><li>Median survival is 2 to 3 years for patients healthy enough to receive chemotherapy</li><li>Survival depends on molecular subtype, comorbid illnesses, and fitness level</li><li>KRAS/NRAS wild-type tumors respond to monoclona</li></ul><hr><a href=#take-home-message><h2 id=take-home-message><span class=hanchor arialabel=Anchor># </span>Take Home message</h2></a><ul><li>Third most common cause of cancer mortality in the US</li><li>53,200 deaths projected in 2020</li><li><strong>70-75%</strong> of metastatic CRC patients survive beyond 1 year</li><li>Systemic therapy is primary treatment for unresectable metastatic CRC</li><li>Tailoring treatment to tumor&rsquo;s molecular and pathologic features improves survival</li><li>Genomic profiling detects somatic variants for effective treatments</li></ul><hr><ul><li>Cetuximab and panitumumab extend median survival by 2-4 months for KRAS/NRAS/BRAF wild-type tumors</li><li>Effective targeted therapies are not yet available for KRAS or NRAS sequence variations</li><li>Combination therapy with BRAF and EGFR inhibitors extended overall survival to 9.3 months<ul><li>for <strong>BRAF V600E sequence variations</strong></li></ul></li><li>Immunotherapy may be used for microsatellite instability or mismatch repair deficiency</li><li>Median overall survival of 31.4 months in previously treated patients with immunotherapy</li></ul><hr><a href=#prototypical-treatment-trajectories-1><h2 id=prototypical-treatment-trajectories-1><span class=hanchor arialabel=Anchor># </span>Prototypical Treatment Trajectories</h2></a><p><img src=https://i.imgur.com/LPCRJVa.png width=auto alt="Figure: height:550px"></p><hr><style scoped>h2{font-size:3em;font-weight:700}section{display:flex;justify-content:center;align-items:center}</style><a href=#the-end><h2 id=the-end><span class=hanchor arialabel=Anchor># </span>THE END</h2></a></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>